Aldeyra Therapeutics upgraded by Oppenheimer with a new price target
$ALDX
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer upgraded Aldeyra Therapeutics from Perform to Outperform and set a new price target of $10.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/3/2024 | $10.00 | Perform → Outperform | Oppenheimer |
| 4/2/2024 | $10.00 | Buy | H.C. Wainwright |
| 4/27/2022 | $15.00 | Buy | H.C. Wainwright |
| 12/21/2021 | $25.00 → $21.00 | Buy | Citigroup |
| 12/21/2021 | $24.00 → $15.00 | Outperform | SVB Leerink |
8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
SCHEDULE 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)
8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company's board of directors. "Chip possesses a wealth of experience leading innovative biotechnology companies," stated Richard H. Douglas, Ph.D., Chairman of the Board at Aldeyra Therapeutics. "We look forward to leveraging his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs in immune-mediated and metabolic diseases." Mr. Clark has more than three decades of leadership experience in the
SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)
SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)
SC 13G - Aldeyra Therapeutics, Inc. (0001341235) (Subject)
Top-Line Data from Dry Eye Chamber Trial and Field Trial Expected in Q2 2025 Pending Positive Results and Discussions with the FDA, New Drug Application Resubmission Expected Mid-Year 2025 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing or safety issues with reproxalap were id
New Drug Application Resubmission Anticipated in 2024 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. Reproxalap was statistically superior to vehicle for the prespecified primary endpoint of ocular discomfort (P=0.004), a U.S. Food and Drug Administration (FDA)-accepted symptom of dry e
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, August 8, 2024, at 9:00 a.m. (ET) to provide top-line results from the Phase 3 dry eye disease clinical trial of reproxalap. The dial-in numbers are (888) 596-4144 for domestic callers and (646) 968-2525 for international callers. The access code is 7321123. A live audio webcast of the conference call also will be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com. After the live webcast, the event will remain archived on Aldeyra's website for 90 days. About Aldeyra Aldeyra Therapeutics is a biotechnology company devoted to di
Oppenheimer upgraded Aldeyra Therapeutics from Perform to Outperform and set a new price target of $10.00
H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $10.00
H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $15.00
4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
3 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company's board of directors. "Chip possesses a wealth of experience leading innovative biotechnology companies," stated Richard H. Douglas, Ph.D., Chairman of the Board at Aldeyra Therapeutics. "We look forward to leveraging his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs in immune-mediated and metabolic diseases." Mr. Clark has more than three decades of leadership experience in the
Top-Line Data from Dry Eye Chamber Trial and Field Trial Expected in Q2 2025 Pending Positive Results and Discussions with the FDA, New Drug Application Resubmission Expected Mid-Year 2025 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing or safety issues with reproxalap were id
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference in Miami, Florida. Dr. Brady's conversation with Marc Goodman, Senior Managing Director, Neuroscience, is scheduled to begin at 9:20 a.m. ET Monday, March 10, 2025. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the fireside chat, the webcast w